Participant flow

An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis · Source last updated 2018-07-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants with granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) or microscopic polyangiitis (MPA) who received rituximab as per investigator's discretion were followed for a maximum of 4.32 years.

   id

   FG000

   title

   Rituximab

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         9

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Lost to Follow-up

   3. reasons

      1. group Id

         FG000

         num Subjects

         8

      type

      Withdrawal by Subject

   4. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Reason not specified

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         97

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         72

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         25

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

A total of 100 participants were enrolled in 15 investigational sites in United States. 3 participants out of 100 enrolled participants were not included in the analysis population as that site became unresponsive.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice